Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes

Trial Profile

Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Nivolumab (Primary) ; Veliparib (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
    • 01 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 19 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top